The study seeks to identify proteomic profiles in blood that can predict cognitive decline in people with an increased risk of developing Alzheimer's disease.
The results are compiled in a study published in iScience, led by the Hospital del Mar Medical Research Institute and the Barcelonaβeta Brain Research Center, center of the Pasqual Maragall Foundation.
The vice-president of the Pasqual Maragall Foundation will head the new independent and consultative body set up by the Ministry of Science and Innovation with the aim of ensuring responsible science and the integrity of its professionals.
The researcher defended the thesis, developed at the BBRC and focused on biomarkers in preclinical Alzheimer's fluids, in April 2022.
The data have been compared with Alzheimer's biomarkers of 2,300 people from four cohorts, including participants without cognitive alterations from the ALFA Study, promoted by the ”la Caixa” Foundation.
Researchers from the research center of the Pasqual Maragall Foundation have taken part in these conferences dedicated to the latest developments in Alzheimer's research and the future of the European EPAD and AMYPAD projects.
More than 80 researchers have attended the Biomarkers Workshop, a scientific event with great international impact, organised by the Barcelonaβeta Brain Research Center.
Thanks to this neuroimaging technique, widely used in the field of research, deposits of the Alzheimer’s disease associated amyloid-β protein in the brain can be detected and evaluated.
The sessions, directed by the research center of the Pasqual Maragall Foundation, will feature presentations by leading experts in the field of neuroscience.